Literature DB >> 11401055

Serum procalcitonin in pneumococcal pneumonia in children.

M Korppi1, S Remes.   

Abstract

Serum procalcitonin (PCT), a marker of bacterial infection, was measured in children with pneumonia to examine whether PCT can be used to screen pneumococcal (PNC) from viral pneumonia. The number of patients was 132; mean age 3.0 yrs, and 64% were males. In all cases, pneumonia was radiologically confirmed, being alveolar in 46 and interstitial in 86 cases. The aetiology of infection was studied by a panel of serological tests for PNC, for five other respiratory bacteria and for seven common respiratory viruses. PNC infection was found in 25, mixed viral-PNC infections in 13 and viral infection in 17 cases. In general, serum PCT was not associated with the type or aetiology of pneumonia. PCT values were >1.0 mg.L(-1) in 40% of PNC cases, as compared to 12-15% in viral or mixed cases, respectively (p<0.05). PCT values were significantly higher in >2 yrs old children than in younger ones. The cut-off limits of 0.5 ng.mL(-1), 1.0 ng.mL(-1) and 2.0 ng.mL(-1) were tested for screening between PNC and viral pneumonia. The highest sensitivity of 55% was found at the 0.5 ng.mL(-1) cut-off level, whereas the highest specificity of 88% was reached at the level of 1.0 ng.mL(-1). The likelihood ratios, however, were far from optimal for both the positive and negative results. Although marginally higher in pneumococcal pneumonia than in viral pneumonia, serum procalcitonin cannot be used to discriminate between these two types of pneumonia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401055     DOI: 10.1183/09031936.01.17406230

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

1.  BTS guidelines for the management of pleural infection in children.

Authors:  I M Balfour-Lynn; E Abrahamson; G Cohen; J Hartley; S King; D Parikh; D Spencer; A H Thomson; D Urquhart
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

2.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

3.  The role of procalcitonin in respiratory infections.

Authors:  Laura Certain; Philipp Schuetz
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

4.  Biomarkers for community-acquired pneumonia in the emergency department.

Authors:  Todd A Florin; Lilliam Ambroggio
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 5.  Community-acquired pneumonia in children: issues in optimizing antibacterial treatment.

Authors:  Matti Korppi
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care.

Authors:  Anette Holm; Svend S Pedersen; Joergen Nexoe; Niels Obel; Lars P Nielsen; Ole Koldkjaer; Court Pedersen
Journal:  Br J Gen Pract       Date:  2007-07       Impact factor: 5.386

7.  Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia.

Authors:  Shabir A Madhi; Jayvant R Heera; Locadiah Kuwanda; Keith P Klugman
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

8.  Sensitivity and Specificity of Soluble Triggering Receptor Expressed on Myeloid Cells-1, Midregional Proatrial Natriuretic Peptide and Midregional Proadrenomedullin for Distinguishing Etiology and to Assess Severity in Community-Acquired Pneumonia.

Authors:  Susanna Esposito; Maria Di Gangi; Fabio Cardinale; Eugenio Baraldi; Ilaria Corsini; Liviana Da Dalt; Pier Angelo Tovo; Antonio Correra; Alberto Villani; Oliviero Sacco; Laura Tenero; Piera Dones; Monia Gambino; Alberto Zampiero; Nicola Principi
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

Review 9.  Biomarkers in Pediatric Community-Acquired Pneumonia.

Authors:  Nicola Principi; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2017-02-19       Impact factor: 5.923

Review 10.  Is Procalcitonin Useful in Pediatric Critical Care Patients?

Authors:  Sara Bobillo-Perez; Javier Rodríguez-Fanjul; Iolanda Jordan Garcia
Journal:  Biomark Insights       Date:  2018-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.